Omicron-specific COVID-19 vaccine - BioNTech/Pfizer
Latest Information Update: 28 Feb 2025
At a glance
- Originator BioNTech
- Developer BioNTech; Pfizer
- Class COVID-19 vaccines; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In volunteers, In adults) in Germany (Parenteral)
- 28 Feb 2025 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections(In volunteers, In adults) in USA (Parenteral)
- 25 Jan 2022 Clinical trials in COVID-2019 infections in USA (Parenteral), Germany (Parenteral)